Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Outlook Therapeutics (OTLK) over the last 7 years, with Q4 2025 value amounting to -$14.9 million.

  • Outlook Therapeutics' Cash from Operations fell 3621.46% to -$14.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$55.8 million, marking a year-over-year decrease of 6465.29%. This contributed to the annual value of -$51.8 million for FY2025, which is 2465.98% up from last year.
  • According to the latest figures from Q4 2025, Outlook Therapeutics' Cash from Operations is -$14.9 million, which was down 3621.46% from -$12.4 million recorded in Q3 2025.
  • Outlook Therapeutics' 5-year Cash from Operations high stood at -$11.0 million for Q4 2024, and its period low was -$16.6 million during Q1 2025.